A Phase I, Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given By IV Infusion to Patients With Advanced Or Metastatic Cancer
www.ClinicalTrials.Gov. Identifer: NCT01300533. Accessed July 17
www.ClinicalTrials.Gov. A phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer. http://clinicaltrials.gov/ct2/show/NCT01300533. Identifer: NCT01300533. Accessed July 17, 2012.
(2012)
2
84875233739
Abstract LB-452: A phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer
Abstract LB-452
Summa J, LoRusso PM, Eisenberg P, et al. Abstract LB-452: a phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer. Cancer Res (AACR Annual Meeting Abstracts). 2012;72(8 suppl): Abstract LB-452.
Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection
Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano. 2012;24;6:696-704.
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery
Karve S, Werner ME, Sukumar R, et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci U S A. 2012;109:8230-8235.
Nanotechnology in drug delivery and tissue engineering: From discovery to applications
Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10:3223-3230.
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a diferentiated pharmacological profle
Hrkach J, Von Hof D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a diferentiated pharmacological profle. Sci Transl Med. 2012;4:128ra39.
Antibody targeting of liposomes: Cell specifcity obtained by conjugation of F(ab')2 to vesicle surface
Heath TD, Fraley RT, Papahdjopoulos D. Antibody targeting of liposomes: cell specifcity obtained by conjugation of F(ab')2 to vesicle surface. Science. 1980;210:539-541.